Abstract
Whole-body distribution of iodine 123 metaiodobenzylguanidine (123I-mIBG) was evaluated in 27 patients with hypertrophic cardiomyopathy (HCM). At 1 and 4 h after injection, anterior and posterior whole body images were obtained with a dual-headed, camera computer system. Patients were classified into three groups based on the septal wall thickness as determined by echocardiography: group 1 consisted of 7 patients with ≤ 15 mm septal thickness, group 2 included 12 patients with 16–19 mm septal thickness, and group 3 included 6 patients with ≽ 20 mm septal thickness. Although the myocardial mIBG uptakes at 1 h were similar among these groups (1.84% ± 0.19%, 1.95% ± 0.38%, 1.98% ± 0.57%, respectively; NS), mIBG washout from the heart in group 3 was faster than in groups 1 and 2 (31.5% ± 13.0% vs. 15.8% ± 11.0% (group 1,P < 0.05), 17.6% ± 7.3% (group 2,P < 0.01)). There was a significant positive correlation between mIBG washout from the heart and septal thickness, with correlation coefficientr=0.52 (P < 0.01). The liver, lung, parotid gland, spleen and skeletal muscle showed similar mIBG uptake and washout among the three groups. We conclude from these data that mIBG washout from the heart in HCM was faster in patients with severe hypertrophy than in patients with mild to moderate hypertrophy, and hence it may be a useful parameter for evaluating the severity of altered adrenergic innervation and activities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baulieu JL, Guilloteau D, Delisle MJ, Perdrisot R, Gradet P, Delepine N, Baulieu F, Doupond JL, Talbot JN, Coutris G, Calmettes C, French Medullary Cancer Study Group (1987) Radioiodinated metaiodobenzylguanidine (mIBG) uptake in medullary thyroid cancer (MTC). A French cooperative study. Cancer 60:2189–2194
Ciro E, Nichols PF III, Maron BJ (1983) Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy. Circulation 67:1227–1233
Dae MW, O'Connell JW, Botvinik EH, Ahearn T, Yee E, Huberty JP, Mori H, Chin MC, Hattner RS, Herre JM, Munoz L (1989 a) Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation 79:634–644
Dae MW, O'Connell WC, Munoz L, Newman D, Botvinik E, Chin M (1989 b) Scintigraphic assessment of myocardial nerve development with mIBG washout maps. J Nucl Med 30:810 (abstr)
Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR (1989) Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 30:1182–1191
Goodwin JF (1982) The frontiers of cardiomyopathy. Br Heart J 48:1–18
Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, Ugolini V, Akers MS, Hansen C, Buja LM, Parkey RW, Willersn JT (1988) Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 78:1192–1199
Kimming B, Brandeis WE, Eisenhut M, Bubeck B, Hermann HJ, Winkel K (1984) Scintigraphy of a neuroblastoma with I-131 metaiodobenzylguanidine. J Nucl Med 25:773–775
Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue P, Shinohara S (1986) Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 27:84–89
Paton DM (1980) Neuronal transport of noradrenaline and dopamine. Pharmacology 21:85–92
Perloff JK (1981) Pathogenesis of hypertrophic cardiomyopathy: hypotheses and speculations. Am Heart J 101:219–226
Rabinovitch MA, Rose CP, Rouleau JL, Chartrand C, Wieland DM, Lepanto L, Legault F, Suissa S, Rosenthall L, Burgess JH (1987) Metaiodobenzylguanidine [131-I] scintigraphy detects impaired myocardial sympathetic neuronal transport function of canine mechanical-overloaded heart failure. Circ Res 61:797–804
Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26:576–585
Shen SW, Sisson JC, Shulkin B, Fung A, Shapiro B, Meyers L, Ackerman R, Mallett S (1986) I-123-metaiodobenzylguanidine (1-123-mIBG) as an index of neuron integrity following myocardial infarction. J Nucl Med 27:949 (abstr)
Sisson JC, Sherman WP, Manger TJ, Tobes MC, Jacques S Jr (1987 a) Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 28:1620–1624
Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, Glowniak JV, Sherman P, Beierwaltes WH (1987 b) Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 28:1625–1636
Sisson JC, Wieland DM, Jacques S Jr, Sherman P, Fisher S, Mallette S, Meyers L, Mangner TJ (1987c) Radiolabeled metaiodobenzylguanidine and the adrenergic neurons of salivary glands. Am J Physiol Imaging 2:1–9
Tobes MC, Jaques S, Wieland DM, Sisson JC (1985) Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 26:897–907
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Taki, J., Nakajima, K., Bunko, H. et al. Whole-body distribution of iodine 123 metaiodobenzylguanid1ne in hypertrophic cardiomyopathy: significance of its washout from the heart. Eur J Nucl Med 17, 264–268 (1990). https://doi.org/10.1007/BF00812368
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00812368